FHL2 suppresses growth and differentiation of the colon cancer cell line HT-29

Oncology Reports

Volumn 23, Issue 6, 2010, Pages 1669-1674

  Amann, Thomas ^a   Egle, Yvonne ^a   Bosserhoff, Anja Katrin ^b   Hellerbrand, Claus ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Colorectal cancer; Differentiation; E cadherin; FHL2; HT 29; NF B; Proliferation

Indexed keywords

FOUR AND A HALF LIM PROTEIN 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN; FHL2 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; LIM HOMEODOMAIN PROTEIN; MESSENGER RNA; MUSCLE PROTEIN; TRANSCRIPTION FACTOR;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL DIFFERENTIATION; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; APOPTOSIS; CELL CYCLE; CFU COUNTING; COLON TUMOR; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; COLONY-FORMING UNITS ASSAY; HOMEODOMAIN PROTEINS; HUMANS; LIM-HOMEODOMAIN PROTEINS; MUSCLE PROTEINS; NF-KAPPA B; PHOSPHORYLATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTORS;

EID: 77951730050     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000810     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics 2009. CA Cancer J Clin 59: 225-249, 2009.
2. Li FY and Lai MD: Colorectal cancer, one entity or three. J Zhejiang Univ Sci B 10: 219-229, 2009.
3. Chan KK, Tsui SK, Lee SM, Luk SC, Liew CC, Fung KP, Waye MM and Lee CY: Molecular cloning and characterization of FHL2, a novel LIM domain protein preferentially expressed in human heart. Gene 210: 345-350, 1998.
4. Sanchez-Garcia I, Osada H, Forster A and Rabbitts TH: The cysteine-rich LIM domains inhibit DNA binding by the associated homeodomain in Isl-1. EMBO J 12: 4243-4250, 1993.
5. Bach I: The LIM domain: regulation by association. Mech Dev 91: 5-17, 2000.
6. Johannessen M, Moller S, Hansen T, Moens U and Van Ghelue M: The multifunctional roles of the four-and-a-half-LIM only protein FHL2. Cell Mol Life Sci 63: 268-284, 2006.
7. Labalette C, Nouet Y, Sobczak-Thepot J, Armengol C, Levillayer F, Gendron MC, Renard CA, Regnault B, Chen J, Buendia MA and Wei Y: The LIM-only protein FHL2 regulates cyclin D1 expression and cell proliferation. J Biol Chem 283: 15201-15208, 2008.
8. Martin B, Schneider R, Janetzky S, Waibler Z, Pandur P, Kuhl M, Behrens J, von der Mark K, Starzinski-Powitz A and Wixler V: The LIM-only protein FHL2 interacts with beta-catenin and promotes differentiation of mouse myoblasts. J Cell Biol 159: 113-122, 2002.
9. Wixler V, Hirner S, Muller JM, Gullotti L, Will C, Kirfel J, Gunther T, Schneider H, Bosserhoff A, Schorle H, Park J, Schule R and Buettner R: Deficiency in the LIM-only protein Fhl2 impairs skin wound healing. J Cell Biol 177: 163-172, 2007.
10. Hayashi H, Nakagami H, Takami Y, Koriyama H, Mori M, Tamai K, Sun J, Nagao K, Morishita R and Kaneda Y: FHL-2 suppresses VEGF-induced phosphatidylinositol 3-kinase/Akt activation via interaction with sphingosine kinase-1. Arterioscler Thromb Vasc Biol 29: 909-914, 2009.
11. Philippar U, Schratt G, Dieterich C, Muller JM, Galgoczy P, Engel FB, Keating MT, Gertler F, Schule R, Vingron M and Nordheim A: The SRF target gene Fhl2 antagonizes RhoA/MAL-dependent activation of SRF. Mol Cell 16: 867-880, 2004.
12. Kleiber K, Strebhardt K and Martin BT: The biological relevance of FHL2 in tumour cells and its role as a putative cancer target. Anticancer Res 27: 55-61, 2007.
13. Genini M, Schwalbe P, Scholl FA, Remppis A, Mattei MG and Schafer BW: Subtractive cloning and characterization of DRAL, a novel LIM-domain protein down-regulated in rhabdomyosarcoma. DNA Cell Biol 16: 433-442, 1997.
14. Kinoshita M, Nakagawa T, Shimizu A and Katsuoka Y: Differently regulated androgen receptor transcriptional complex in prostate cancer compared with normal prostate. Int J Urol 12: 390-397, 2005.
15. Ding L, Wang Z, Yan J, Yang X, Liu A, Qiu W, Zhu J, Han J, Zhang H, Lin J, Cheng L, Qin X, Niu C, Yuan B, Wang X, Zhu C, Zhou Y, Li J, Song H, Huang C and Ye Q: Human four-and-a-half LIM family members suppress tumor cell growth through a TGF-beta-like signaling pathway. J Clin Invest 119: 349-361, 2009.
16. Chen D, Xu W, Bales E, Colmenares C, Conacci-Sorrell M, Ishii S, Stavnezer E, Campisi J, Fisher DE, Ben Ze'ev A and Medrano EE: SKI activates Wnt/beta-catenin signaling in human melanoma. Cancer Res 63: 6626-6634, 2003.
17. Gabriel B, Mildenberger S, Weisser CW, Metzger E, Gitsch G, Schule R and Muller JM: Focal adhesion kinase interacts with the transcriptional coactivator FHL2 and both are overexpressed in epithelial ovarian cancer. Anticancer Res 24: 921-927, 2004.
18. Gabriel B, Fischer DC, Orlowska-Volk M, Zur Hausen A, Schule R, Muller JM and Hasenburg A: Expression of the transcriptional coregulator FHL2 in human breast cancer: a clinicopathologic study. J Soc Gynecol Investig 13: 69-75, 2006.
19. Li M, Wang J, Ng SS, Chan CY, Chen AC, Xia HP, Yew DT, Wong BC, Chen Z, Kung HF and Lin MC: The four-and-a-half-LIM protein 2 (FHL2) is overexpressed in gliomas and associated with oncogenic activities. Glia 56: 1328-1338, 2008.
20. Tanahashi H and Tabira T: Alzheimer's disease-associated presenilin 2 interacts with DRAL, an LIM-Domain protein. Hum Mol Genet 9: 2281-2289, 2000.
21. Wang J, Yang Y, Xia HH, Gu Q, Lin MC, Jiang B, Peng Y, Li G, An X, Zhang Y, Zhuang Z, Zhang Z, Kung HF and Wong BC: Suppression of FHL2 expression induces cell differentiation and inhibits gastric and colon carcinogenesis. Gastroenterology 132: 1066-1076, 2007.
22. Muhlbauer M, Allard B, Bosserhoff AK, Kiessling S, Herfarth H, Rogler G, Scholmerich J, Jobin C and Hellerbrand C: Differential effects of deoxycholic acid and taurodeoxycholic acid on NFKappa B signal transduction and IL-8 gene expression in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol 286: 1000-1008, 2004.
23. Hellerbrand C, Amann T, Schlegel J, Wild P, Bataille F, Spruss T, Hartmann A and Bosserhoff AK: The novel gene MIA2 acts as a tumour suppressor in hepatocellular carcinoma. Gut 57: 243-251, 2007.
24. Hellerbrand C, Muhlbauer M, Wallner S, Schuierer M, Behrmann I, Bataille F, Weiss T, Scholmerich J and Bosserhoff AK: Promoter-hypermethylation is causing functional relevant downregulation of methylthioadenosine phosphorylase (MTAP) expression in hepatocellular carcinoma. Carcinogenesis 27: 64-72, 2006.
25. Kiessling S, Muller-Newen G, Leeb SN, Hausmann M, Rath HC, Strater J, Spottl T, Schlottmann K, Grossmann J, Montero-Julian FA, Scholmerich J, Andus, T, Buschauer A, Heinrich PC and Rogler G: Functional expression of the interleukin-11 receptor alpha-chain and evidence of antiapoptotic effects in human colonic epithelial cells. J Biol Chem 279: 10304-10315, 2004.
26. Maegdefrau U, Amann T, Winklmeier A, Braig S, Schubert T, Weiss TS, Schardt K, Warnecke C, Hellerbrand C and Bosserhoff AK: Bone morphogenetic protein 4 is induced in hepatocellular carcinoma by hypoxia and promotes tumour progression. J Pathol 218: 520-529, 2009.
27. Chartier NT, Laine M, Gout S, Pawlak G, Marie CA, Matos P, Block MR and Jacquier-Sarlin MR: Laminin-5-integrin interaction signals through PI 3-kinase and Rac1b to promote assembly of adherens junctions in HT-29 cells. J Cell Sci 119: 31-46, 2006.
28. Simiantonaki N, Kurzik-Dumke U, Karyofylli G, Jayasinghe C and Kirkpatrick CJ: Loss of E-cadherin in the vicinity of necrosis in colorectal carcinomas: association with NFkappaB expression. Int J Oncol 31: 269-275, 2007.
29. Kuphal S, Poser I, Jobin C, Hellerbrand C and Bosserhoff AK: Loss of E-cadherin leads to upregulation of NFkappaB activity in malignant melanoma. Oncogene 23: 8509-8519, 2004.
30. Kanazawa T, Watanabe T, Kazama S, Tada T, Koketsu S and Nagawa H: Poorly differentiated adenocarcinoma and mucinous carcinoma of the colon and rectum show higher rates of loss of heterozygosity and loss of E-cadherin expression due to methylation of promoter region. Int J Cancer 102: 225-229, 2002.
31. Kokura S, Yoshida N, Imamoto E, Ueda M, Ishikawa T, Uchiyama K, Kuchide M, Naito Y, Okanoue T and Yoshikawa T: Anoxia/reoxygenation down-regulates the expression of E-cadherin in human colon cancer cell lines. Cancer Lett 211: 79-87, 2004.
32. Bai S, Kitaura H, Zhao H, Chen J, Muller JM, Schule R, Darnay B, Novack DV, Ross FP and Teitelbaum SL: FHL2 inhibits the activated osteoclast in a TRAF6-dependent manner. J Clin Invest 115: 2742-2751, 2005.
33. Qiao L, Wang Y, Pang R, Wang J, Dai Y, Ma J, Gu Q, Li Z, Zhang Y, Zou B, Lan HY and Wong BC: Oncogene functions of FHL2 are independent from NF-KappaBIalpha in gastrointestinal cancer. Pathol Oncol Res 15: 31-36, 2009.